MannKind Corporation - Common Stock (NQ:MNKD)

5.140 +0.110 (+2.19%)

Streaming Delayed Price Updated: 12:51 PM EST, Nov 24, 2025 Add to My Watchlist

Price and Volume

Volume	795,365
Open	5.160
Bid (Size)	5.140 (2,500)
Ask (Size)	5.150 (3,600)
Prev. Close	5.030
Today's Range	5.070 - 5.190
52wk Range	3.381 - 7.070
Shares Outstanding	264,305,532
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

MannKind to Present at the Jefferies Global Healthcare Conference

November 11, 2025

From MannKind

Via GlobeNewswire

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

November 10, 2025

From MannKind

Via GlobeNewswire

Performance

YTD	-22.1%	-22.1%
1 Month	-3.2%	-3.2%
3 Month	+31.8%	+31.8%
6 Month	+22.2%	+22.2%
1 Year	-23.5%	-23.5%

More News

MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

November 06, 2025

From MannKind

Via GlobeNewswire

MannKind Stock Nears Breakout As FDA Reviews First New Insulin For Kids In A Century ↗

November 06, 2025

Via Stocktwits

MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters ↗

November 05, 2025

Via Stocktwits

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results ↗

September 02, 2025

Via Stocktwits

MannKind Corp (NASDAQ:MNKD) Reports Q3 2025 Earnings Beat, Shares Rise ↗

November 05, 2025

Via Chartmill

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

November 05, 2025

From MannKind

Via GlobeNewswire

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

October 29, 2025

From MannKind

Via GlobeNewswire

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

October 13, 2025

From MannKind

Via GlobeNewswire

MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together ↗

August 27, 2025

Via Stocktwits

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

October 07, 2025

From MannKind

Via GlobeNewswire

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

September 29, 2025

From MannKind

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

September 09, 2025

Via Benzinga

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

September 02, 2025

Via Chartmill

Tuesday's pre-market session: top gainers and losers ↗

September 02, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 02, 2025

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), HanesBrands Financial Corp. (NYSE - HBI)

August 28, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

MannKind to Present at Upcoming Investor Conferences

August 27, 2025

From MannKind

Via GlobeNewswire

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

August 27, 2025

From MannKind

Via GlobeNewswire

MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish ↗

August 25, 2025

Via Stocktwits

MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal ↗

August 25, 2025

Via Benzinga

MannKind Corporation to Acquire scPharmaceuticals: More Details Inside ↗

August 25, 2025

Via Stocktwits

Frequently Asked Questions

Is MannKind Corporation - Common Stock publicly traded?

Yes, MannKind Corporation - Common Stock is publicly traded.

What exchange does MannKind Corporation - Common Stock trade on?

MannKind Corporation - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for MannKind Corporation - Common Stock?

The ticker symbol for MannKind Corporation - Common Stock is MNKD on the Nasdaq Stock Market

What is the current price of MannKind Corporation - Common Stock?

The current price of MannKind Corporation - Common Stock is 5.140

When was MannKind Corporation - Common Stock last traded?

The last trade of MannKind Corporation - Common Stock was at 11/24/25 12:51 PM ET

What is the market capitalization of MannKind Corporation - Common Stock?

The market capitalization of MannKind Corporation - Common Stock is 1.36B

How many shares of MannKind Corporation - Common Stock are outstanding?

MannKind Corporation - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.